ROCKVILLE, Md., March 6, 2009 (GLOBE NEWSWIRE) -- Nabi Biopharmaceuticals (Nasdaq:NABI) today announced that Dr. Raafat Fahim, President and Chief Executive Officer, will participate in the Noble Financial Capital Markets Boston Uncommon Conference to be held March 12, 2009 at The Hilton Boston Financial District Hotel in Boston, MA. Dr. Fahim's presentation is scheduled for 12:15 p.m. EDT.
You can access the web cast of this presentation on the company's "Events and Webcasts" page at www.nabi.com or at http://hosted.mediasite.com/hosted5/Viewer/?peid=e79414abbac74117a3c6a10dc0437108
About Nabi Biopharmaceuticals
Nabi Biopharmaceuticals leverages its experience and knowledge in powering the immune system to develop products that target serious medical conditions in the areas of nicotine addiction and gram-positive bacterial infections. Nabi Biopharmaceuticals is currently developing NicVAX(r) (Nicotine Conjugate Vaccine), an innovative and proprietary investigational vaccine for treatment of nicotine addiction and prevention of smoking relapse, and PentaStaphTM (Pentavalent S. aureus Vaccine), a vaccine designed to protect against the most dangerous and prevalent strains of S. aureus bacterial infections. The company is headquartered in Rockville, Maryland. For additional information about Nabi Biopharmaceuticals, please visit our Web site: http://www.nabi.com.